• Teijin launched joint research with Teijin Regenet, Shinshu University Hospital to strengthen Japan’s CAR-T cell therapy manufacturing capacity.
• Work targets manufacturing technology upgrades, broader domestic production infrastructure for cell and gene therapies, addressing staffing and facility constraints.
• Shinshu’s Cell Processing Center will support studies on automation, efficiency gains, quality testing, quality-control methods for future manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.